Abstract
Numerous dermal contact products, such as drugs or cosmetics, are applied on the skin, the first protective
barrier to their entrance into the organism. These products contain various xenobiotic molecules that can penetrate
the viable epidermis. Many studies have shown that keratinocyte metabolism could affect their behavior by biotransformation.
While aiming for detoxification, toxic metabolites can be produced. These metabolites may react with
biological macromolecules often leading to sensitization reactions. After passing through the epidermis, xenobiotics
can reach the vascularized dermis and therefore, be bioavailable and distributed into the entire organism. To highlight
these mechanisms, dermatokinetics, based on the concept of pharmacokinetics, has been developed recently. It
provides information on the action of xenobiotics that penetrate the organism through the dermal route. The purpose
of this review is first to describe and synthesize the dermatokinetics mechanisms to consider when assessing the
absorption of a xenobiotic through the skin. We focus on skin absorption and specifically on skin metabolism, the
two main processes involved in dermatokinetics. In addition, experimental models and methods to assess dermatokinetics
are described and discussed to select the most relevant method when evaluating, in a specific context, dermatokinetics
parameters of a xenobiotic. We also discuss the limits of this approach as it is notably used for risk assessment
in the industry where scenario studies generally focus only on one xenobiotic and do not consider interactions
with the rest of the exposome. The hypothesis of adverse effects due to the combination of chemical substances
in contact with individuals and not to a single molecule, is being increasingly studied and embraced in the scientific
community.
Keywords:
In vitro models, toxicity, metabolism, drugs, xenobiotics, dermatokinetics.
Graphical Abstract
[1]
Kwon, Y. Handbook of Essential Pharmacokinetics, Pharmacodynamics
and Drug Metabolism for Industrial Scientists; Springer:
Amsterdam: Netherlands, 2001.
[7]
Zanger, U.M.; Schwab, M. Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol. Ther., 2013, 138, 103-141.
[10]
Jancova, P.; Anzenbacher, P.; Anzenbacherova, E. Phase II Drug Metabolizing Enzymes. Biomed. Pap., 2010, 154, 103-116.
[11]
Calabrese, E.J. Principles of Animal Extrapolation; CRC Press: Boca Raton, FL, USA, 1991.
[16]
Rowland, M.; Tozer, T.N. Clinical Pharmacokinetics: Concepts and Applications; Lea & Febiger: Philadelphia, 1989.
[31]
Smith, C.; Hotchkiss, S. Allergic Contact Dermatitis: Chemical and Metabolic Mechanisms; Taylor & Francis: Oxfordshire, 2001.
[39]
Lepoittevin, P. La peau: Acteur majeur du métabolisme. Prog. En Derm.-Allergol. Lille, 2004, 10, 153.
[64]
Wiebel, F.J.; Gelboin, H.V. Cutaneous carcinogenesis: Metabolic interaction of chemical carcinogens with skin. In: Comprehensive Physiol-ogy; John Wiley & Sons, Inc., 2010.
[67]
Barratt, M.D.; Basketter, D.A. Possible origin of the skin sensitization potential of isoeugenol and related compounds. (I). Preliminary studies of potential reaction mechanisms. Contact Dermat., 1992, 27, 98-104.
[73]
Orfila, M-J-B. Treatise on Toxicology; Fortin; Masson: Paris, 1843.
[77]
FDA. Topical Dermatological Drug Product NDAs and ANDAs -In vivo Bioavailability, Bioequivalence, in vitro Release, and Associated Studies; Food and Drug Agency: Rockville, MD, 1998.
[82]
Jacques, C. Study of the diffusion and cutaneous metabolism of
xenobiotics on preserved pig ear skin in comparison with the liver,
Doctoral Thesis, Université de Toulouse, 2010.
[84]
Wilkinson, G.R. Prediction of In vivo Parameters of Drug Metabolism and Distribution from In vitro Studies; National Academies Press: US, 1987.
[120]
Guerriaud, M. Droit pharmaceutique; Elsevier Masson, 2016.